Turnstone Biologics Acquires Myst Therapeutics
January 20, 2021
Turnstone Biologics Corp., a privately held clinical-stage biotechnology company, has acquired California-based Myst Therapeutics to integrate Myst’s tumor-infiltrating lymphocyte (TIL) selection and expansion platform into Turnstone’s oncolytic virus and cell therapy pipeline. The acquisition grants Turnstone full access to Myst’s R&D capabilities, development collaborations, and a TIL program with a lead candidate expected to enter the clinic soon; financial terms were not disclosed.
- Buyers
- Turnstone Biologics Corp.
- Targets
- Myst Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
United Therapeutics Acquires Thymmune Therapeutics
July 3, 2026
Biotechnology
United Therapeutics announced it has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing thymic regenerative cell therapies. The deal includes $140 million paid in cash upfront, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.
-
Taconic Biosciences Acquires TransCure bioServices
January 20, 2026
Biotechnology
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
Millstone Medical Outsourcing Acquires MycoScience
November 14, 2022
Healthcare Services
Millstone Medical Outsourcing, an Arlington Capital Partners portfolio company, has completed the acquisition of MycoScience, a Willington, Connecticut-based provider of medical device and pharmaceutical laboratory and environmental testing services. The acquisition adds advanced laboratory and regulatory testing capabilities to Millstone's post-manufacturing and aftermarket services, enabling more in-house testing, faster time to market, and expanded end-to-end offerings.
-
Bristol Myers Squibb Acquires Turning Point Therapeutics
June 3, 2022
Healthcare Services
Bristol Myers Squibb will acquire Turning Point Therapeutics in a $4.1 billion, all-cash transaction at $76.00 per share under a definitive merger agreement. The deal was originally expected to close in Q3 2022, and the acquisition was completed in August 2022.
-
Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals
December 7, 2021
Pharmaceuticals
Xcovery Holdings, an oncology-focused biopharmaceutical company, has acquired a majority and controlling stake in Meryx, Inc., a clinical-stage immuno-oncology company based in Chapel Hill, North Carolina. The deal aims to accelerate Meryx's clinical and preclinical drug development programs for small-molecule oncology therapies, with strategic support noted from Betta Pharmaceuticals; financial terms were not disclosed.
-
Treadwell Therapeutics Acquires TCRyption Inc.
October 15, 2021
Biotechnology
Treadwell Therapeutics announced it has acquired TCRyption Inc., a TIO Bioventures–backed developer of a novel TCR-identification platform for T cell therapies, in a stock-swap transaction. The acquisition brings the TCRypt platform and a bank of TCR candidates into Treadwell's pre-clinical oncology pipeline to expand its cell-therapy capabilities, with initial TCR programs expected to enter the clinic in early 2023.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.